OncoMatch/Clinical Trials/NCT02830724
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
Is NCT02830724 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Anti-hCD70 CAR transduced PBL and Cyclophosphamide for pancreatic cancer.
Treatment: Cyclophosphamide · Fludarabine · Aldesleukin · Anti-hCD70 CAR transduced PBL — Background: In a new cancer therapy, researchers take a person s blood, select a certain white blood cell to grow in the lab, and then change the genes of these cells using a virus. The cells are then given back to the person. This is called gene transfer. For this study, researchers will modify the person s white blood cells with anti-CD70. Objectives: To see if a gene transfer with anti-CD70 cells can safely shrink tumors and to be certain the treatment is safe. Eligibility: Adults age 18 and older diagnosed with cancer that has the CD70-expressing cancer. Design: Participants will be screened with medical history, physical exam, scans, and other tests. They may by admitted to the hospital. Leukapheresis will be performed. For this, blood is removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. Eligible participants will have an intravenous catheter placed in their upper chest. Over several days, they will get chemotherapy drugs and the anti-CD70 cells. They will recover in the hospital. Participants will take an antibiotic for 6 months after treatment. They will repeat leukapheresis. Participants will visit the clinic every 1-3 months for the first year after treatment, every 6 months for the second year, and then as determined by their physician. Follow-up visits will take 1-2 days. At each visit, participants will have lab tests, imaging studies, and a physical exam. Throughout the study, blood will be taken and participants will have many tests to determine the size and extent of their tumor and the treatment s impact.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Renal Cell Carcinoma
Breast Carcinoma
Melanoma
Ovarian Cancer
Biomarker criteria
Required: CD70 overexpression (≥2+ CD70 positive on ≥50% of cancer cells OR ≥1+ CD70 positive on ≥75% of cancer cells by IHC)
cancer expressing CD70 as assessed by immunohistochemistry of resected tissue (greater than or equal to 2+ CD70 positive on greater than or equal to 50% of cancer cells, or greater than or equal to 1+ CD70 positive on greater than or equal to 75% of cancer cells)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC > 1000/mm3 without filgrastim; WBC ≥ 2500/mm3; Platelet count ≥ 80,000/mm3; Hemoglobin > 8.0 g/dL (transfusion allowed)
Kidney function
Serum creatinine ≤ 1.6 mg/dL
Liver function
Serum ALT/AST ≤ 5.0 times ULN; total bilirubin ≤ 2.0 mg/dL (≤ 3.0 mg/dL if Gilbert's Syndrome)
ANC greater than 1000/mm(3) without the support of filgrastim; WBC greater than or equal to 2500/mm(3); Platelet count greater than or equal to 80,000/mm(3); Hemoglobin > 8.0 g/dL. Subjects may be transfused to reach this cut-off. Serum ALT/AST less than or equal to 5.0 times ULN; Serum creatinine less than or equal to 1.6 mg/dL; Total bilirubin less than or equal to 2.0 mg/dL, except in patients with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- National Institutes of Health Clinical Center · Bethesda, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02830724 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require CD70?
Yes, CD70 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 72 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages